The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Hemophilia B Gene Therapy Market In 2026 And 2030?
The hemophilia b gene therapy market has experienced substantial expansion in recent years. Its valuation is projected to rise from $0.55 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 29.6%. This historical development can be ascribed to advancements in gene delivery technologies, a greater insight into hemophilia b genetics, the broadening of clinical research programs, the growing impact of lifelong replacement therapy, and the presence of specialized treatment centers.
The market for hemophilia b gene therapy is projected to experience rapid expansion over the upcoming years. This market is anticipated to reach a valuation of $2.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 29.8%. Several factors will drive this growth during the projection period, including a rise in gene therapy approvals, increased investments targeting rare disease treatments, a surge in demand for lasting therapeutic effects, the broadening of advanced manufacturing capacities, and the expansion of patient access initiatives. Key trends anticipated within this forecast timeframe encompass significant strides in single-dose curative treatments, an intensifying emphasis on sustained factor ix expression, the ongoing refinement of AAV vector designs, the broadening scope of personalized gene therapy methods, and improved regulatory harmonization for cutting-edge therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp
What Major Factors Are Driving The Hemophilia B Gene Therapy Market Forward?
The growing number of gene therapy clinical trials is anticipated to drive the expansion of the hemophilia B gene therapy market. These trials are research studies designed to assess the safety, effectiveness, and long-term treatment potential of gene-based therapies in human participants. The increase in gene therapy clinical trials is fueled by greater investment from biopharmaceutical companies, developments in viral vector technology, supportive regulatory frameworks, and the necessity to address rare genetic disorders with significant unmet medical needs, including hemophilia B. Hemophilia B gene therapy benefits from this expanding landscape by utilizing established clinical development pathways, regulatory expertise, and manufacturing capabilities linked to in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA) reported that the UK had 193 ongoing advanced therapy clinical trials, similar to 2024, with more than half in early stages, approximately 80% commercially sponsored, and over 80% focused on gene therapies, equally divided between ex vivo and in vivo approaches. Consequently, the increasing cell and gene therapy clinical trials are boosting the growth of the hemophilia B gene therapy market. The increasing embrace of personalized medicine is expected to drive the hemophilia B gene therapy market forward. Personalized medicine is a medical strategy that customizes disease prevention, diagnosis, and treatment based on an individual’s genetic, molecular, or clinical characteristics to enhance therapeutic results and minimize side effects. The growing adoption of personalized medicine is propelled by advances in genomics, better biomarker identification, and increasing regulatory backing for targeted therapies that depart from uniform treatment models. Hemophilia B gene therapy is well-aligned with personalized medicine principles, addressing the root genetic cause of the disease and providing long-term therapeutic advantages through individualized gene-based interventions. These therapies depend on patient-specific genetic and clinical profiling to determine suitability, optimize dosage, and monitor treatment longevity and safety. For instance, in February 2024, the Personalized Medicine Coalition stated that the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. Therefore, the rising adoption of personalized medicine is fueling the growth of the hemophilia B gene therapy market.
What Segment Categories Shape The Hemophilia B Gene Therapy Market Segment Landscape?
The hemophilia b gene therapy market covered in this report is segmented –
1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors
2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B
3) By Treatment Type: On-Demand; Cure; Prophylaxis
4) By Patient Age Group: Geriatric; Adults; Pediatric
5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
Subsegments:
1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors
2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors
3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors
Which Trends Are Impacting The Progress Of The Hemophilia B Gene Therapy Market?
Leading companies within the hemophilia B gene therapy market are increasingly focusing on advancements in next-generation gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance both therapeutic efficacy and safety. These refined AAV-based vector systems act as sophisticated viral delivery mechanisms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, which supports long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a biotechnology firm based in Germany, obtained European Commission approval for HEMGENIX, which stands as the inaugural gene therapy sanctioned for managing hemophilia B. HEMGENIX is indicated for adult patients with severe or moderate hemophilia B who do not have a history of factor IX inhibitors, and it aims to reduce or eliminate the necessity for routine factor IX prophylaxis. Findings from the pivotal HOPE-B clinical study revealed that a significant portion of treated patients no longer required regular factor IX infusions, thereby demonstrating sustained therapeutic benefits and highlighting the potential of advanced AAV-based gene therapies in long-term disease management.
Who Are The Companies Operating Across The Hemophilia B Gene Therapy Market Value Chain?
Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.
Get The Full Hemophilia B Gene Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report
Which Region Has The Greatest Market Share In The Hemophilia B Gene Therapy Market?
North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hemophilia B Gene Therapy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33162&type=smp
Browse Through More Reports Similar to the Global Hemophilia B Gene Therapy Market 2026, By The Business Research Company
Hepatitis Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Acquired Hemophilia Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report
Hemophilia Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model